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ABSTRACT
Purpose This study aimed to assess the activity of two phos-
phodiesterase (PDE) inhibitors, namely GRMS-55 and race-
mic lisofylline ((±)-LSF)) in vitro and in animal models of
immune-mediated disorders.
Methods Inhibition of human recombinant (hr)PDEs and
TNF-alpha release from LPS-stimulated whole rat blood by
the studied compounds were assessed in vitro. LPS-induced
endotoxemia, concanavalin A (ConA)-induced hepatitis, and
collagen-induced arthritis (CIA) animal models were used for
in vivo evaluation. The potency of the investigated compounds
was evaluated using PK/PD and PK/PD/disease progression
modeling.
Results GRMS-55 is a potent hrPDE7A and hrPDE1B in-
hibitor, while (±)-LSF most strongly inhibits hrPDE3A and
hrPDE4B. GRMS-55 decreased TNF-alpha levels in vivo
and CIA progression with IC50 of 1.06 and 0.26 mg/L, while
(±)-LSF with IC50 of 5.80 and 1.06 mg/L, respectively.
Moreover, GRMS-55 significantly ameliorated symptoms of
ConA-induced hepatitis.
Conclusions PDE4B but not PDE4D inhibition appears to be
mainly engaged in anti-inflammatory activity of the studied
compounds. GRMS-55 and (±)-LSF seem to be promising
candidates for future studies on the treatment of immune-
related diseases. The developed PK/PD models may be used
to assess the anti-inflammatory and anti-arthritic potency of
new compounds for the treatment of rheumatoid arthritis and
other inflammatory disorders.
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STAT4 Signal transducer and activator
of transcription 4
TLR4 Toll-like receptor 4
TNF-α Tumor necrosis factor α
INTRODUCTION
Phosphodiesterases (PDEs) are enzymes that hydrolyze the
second messengers – 3′,5′-cyclic adenosine monophosphate
(cAMP) and 3′,5′-cyclic guanosine monophosphate (cGMP).
Eleven types of this enzyme have been described to date.
Some PDEs, namely PDE4, 7, and 8 are specific for cAMP
(1–3), while other, such as PDE5, 6, and 9 for cGMP (4–6).
The remaining family members, i.e., PDE1, 2, 3, 10, and 11
exhibit dual cAMP/cGMP specificity (5,7,8). Due to the ubiq-
uitous expression of PDEs in the mammalian organisms, PDE
inhibitors have emerged as a large group of biologically active
compounds that may be used for the treatment of many dis-
orders. PDE4 and PDE7 are expressed in immune cells, thus,
in recent years, these types of PDE have become a target for
the treatment of immune-related diseases, such as inflamma-
tory and autoimmune disorders (2,9). It is well known that T
cells and increased levels of cytokines, such as TNF-α are
involved in the development of these conditions that include,
among the others, rheumatoid arthritis (RA), autoimmune
hepatitis (AIH), or sepsis. These enzymes by affecting cAMP
levels not only contribute to the regulation of immune re-
sponse with respect to cytokine/chemokine production but
also control lymphocyte proliferation. It has been demonstrat-
ed that an increase in intracellular cAMP levels causes a re-
pression of immune responses. In contrast, a reduction of
cAMP concentrations may exert an immunostimulatory effect
(10). TNF-α is considered a key cytokine in the development
and course of RA, AIH, as well as sepsis (11–13). Thus, anti-
TNF-α therapies are gaining a growing interest as a treatment
option of these diseases. Selective PDE4 and PDE7 inhibitors
have been shown to decrease the release of pro-inflammatory
mediators, such as TNF-α and many other from stimulated
immune cells in vitro as well as in vivo in various animal models
of inflammatory and autoimmune disorders (2). Interestingly,
the results of some pre-clinical studies indicate that an inhibi-
tion of PDE4B subtype is mainly engaged in the anti-
inflammatory activity of selective PDE4 inhibitors (1,14),
while a PDE4D blockage leads to the undesirable effects, such
as nausea and emesis (15).
Therefore, it seems possible that the use of PDE inhibitors
that act on PDE4B and PDE7 and do not demonstrate inhib-
itory activity against PDE4D may offer a better therapeutic
option compared to administration of potent pan-PDE4
inhibitors due to a widened therapeutic window. Such com-
pounds should retain anti-inflammatory activity via an inhibi-
tion of PDE4B and at the same time be devoid of adverse
effects resulting from PDE4D inhibition. Moreover, a PDE7
inhibitory component, which may contribute to the immuno-
regulatory activity of such compounds, could demonstrate an
additional therapeutic advantage in the treatment of inflam-
matory and autoimmune disorders.
The aim of this study was to compare the pharmacological
activity of two PDE inhibitors, namely a new 1,3-dimethylpur-
ine-2,6-dione derivative: 4-(1,3-Dimethyl-2,6-dioxo-8-(phene-
thylamino)-2,3,6,7-tetrahydro-1H-purin-7-yl)-N′-(2-hydroxy-
benzylidene)butanehydrazide (GRMS-55) and racemic liso-
fylline ((±)-LSF) to address the issues raised above. GRMS-
55 has been chosen from the library of newly designed and
synthesized compounds as a moderate inhibitor of PDE4B
and a strong inhibitor of PDE7A (16). (±)-LSF is a drug can-
didate with a moderate PDE4B inhibitory activity tested ear-
lier in pre-clinical and clinical studies as a potential drug for
the treatment of inflammatory and autoimmune disorders
(9,17). In in vitro experiments, the selectivity of the test com-
pounds against various subtypes of human recombinant
(hr)PDEs and their ability to inhibit TNF-α release from
whole rat blood stimulated by lipopolysaccharide (LPS) were
investigated. Both compounds were subsequently evaluated in
in vivo models of inflammatory and autoimmune disorders,
namely in the mice model of AIH induced by an intravenous
(IV) injection of concanavalin A (ConA), in rat endotoxemia
evoked by IV administration of bacterial LPS, which is an
animal model of sepsis, and finally, in the collagen-induced
arthritis (CIA) in rats that is an accepted and well recognized
model of RA. PK/PD and PK/PD/disease (DIS) progression
models have been developed and utilized in this study as the
tools enabling the quantitative assessment of activity of the
investigated and reference compounds.
MATERIALS AND METHODS
Reagents and Compounds
Pentoxifylline (PTX), dimethylsulfoxide (DMSO), polyethylene
glycol (PEG) 400, LPS (E. coli 055:B5 serotype), incomplete
Freund’s adjuvant (IFA), and RPMI 1640 medium were pur-
chased from Sigma-Aldrich (Germany). ConA was purchased
from Santa Cruz Biotechnology (USA). Porcine collagen type
II (2 mg mL−1 in 0.05 M acetic acid) was obtained from
Chondrex, Inc. (USA). Vinpocetine, EHNA, milrinone, zapri-
nast, and papaverine were purchased from Cayman Chemical
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(USA). (±)-LSF was obtained from the Department of Organic
Chemistry, Faculty of Chemistry, Jagiellonian University
(Krakow, Poland). GRMS-55 and 4-(8-((Furan-2-ylmethyl)a-
mino)-1,3-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-7-
yl)-N′-(2-hydroxybenzylidene)butanehydrazide were obtained
from the Department of Medicinal Chemistry and rolipram
from the Department of Organic Chemistry, Faculty of
Pharmacy, Jagiellonian University Medical College (Krakow,
Poland). Temazepam was a gift from Polfa (Poland). Other
reagents and solvents were of HPLC or analytical reagent
grade and were purchased from Merck (Germany).
Animals
10–12-week-old female Lewis rats were used in the CIA exper-
iment and in pharmacokinetic studies and male 8–12-week-old
male Wistar rats were utilized to evoke LPS-induced endotox-
emia model and in pharmacokinetic studies. Female BALB/c
mice weighing 20 ± 3 g were used in ConA-induced hepatitis
model. Lewis rats and BALB/c mice were purchased from the
Mossakowski Medical Research Center Polish Academy of
Sciences (Warsaw, Poland), and Wistar rats were from the
Animal Facility at the Faculty of Pharmacy, Jagiellonian
University Medical College (Krakow, Poland). Animals were
housed in conditions of the constant temperature (21°C) with a
12:12 h light–dark cycle with free access to food and water. All
animal procedures were approved by the First Local Ethical
Committee on Animal Testing at the Jagiellonian University.
All applicable international, national, and institutional guide-
lines for the care and use of animals were followed.
PDE Assay
Inhibitory activity of the investigated and reference compounds
against various subtypes of PDEs was analyzed using the PDE-
Glo Phosphodiesterase Assay following the manufacturer’s in-
struction (Promega Corp., USA). A brief description of this
procedure was presented in the supplementary materials. The
values of IC50, Imax, and γ parameters of the investigated and
reference compounds were estimated using non-linear regres-
sion in PhoenixWinNonlin v. 7.0. Each sample was performed
in quadruplicate and the relative activity of each sample was
calculated as E ¼ sample activity
control activity
 100%. Subsequently, the follow-
ing equation was fitted to the effect-concentration data:
E ¼ E0−Imax  C
γ
C γ þ IC50γ
 
ð1Þ
where E0 is a baseline relative activity of each enzyme in the
absence of a studied compound (fixed to 100%). Imax is the
maximal inhibitory activity of a compound, C is the concentra-
tion of a compound, IC50 is the concentration of a compound
that produces 50% of Imax, and γ is the Hill coefficient.
Stimulation of Whole Rat Blood
Stimulation of whole rat blood by LPS was performed on 96-
well plates. The inhibitory activities of GRMS-55, (±)-LSF,
and reference compounds, i.e., rolipram and PTX were test-
ed. Contents of each well (200 μL) consisted of heparinized rat
blood containing 10 U heparin mL−1 diluted with RPMI-
1640 medium at a ratio of 1:1 (v/v). All compounds were
dissolved in DMSO and added to blood (the final DMSO
concentration in blood was 0.5%) 15min prior to the addition
of LPS dissolved in RPMI-1640 medium to achieve the LPS
concentration of 10 mg L−1. Both, LPS and DMSOwere also
added to control wells at the same concentrations. Additional
control samples (for testing baseline TNF-α levels in blood)
consisted of DMSO (0.5%) without LPS. The incubation
was performed at 37°C in a humidified atmosphere of 5%
CO2 in an MCO-5 AC-PE incubator (PHCbi, Japan). After
6 h of incubation, the plates were centrifuged for 10 min using
PlateFuge MicroCentrifuge (Benchmark Scientific, USA).
The individual plasma samples were harvested and stored at
−80°C until analysis.
Induction of Hepatitis
ConA was dissolved in an appropriate volume of saline for
injections to obtain a concentration of 2 mg mL−1. Each of
the investigated compounds was dissolved in a vehicle com-
posed of DMSO and PEG 400 mixed at a ratio of 1:9 (v/v).
Thirty minutes before ConA administration, mice were
injected intraperitoneally (IP) with the investigated com-
pounds dissolved in the vehicle at a dose of 50 mg kg−1 or
with the corresponding volume of vehicle alone in the case of
control group. ConA was administered by IV route at a dose
of 20 mg kg−1 and 8 h later mice were sacrificed. Blood sam-
ples were harvested from each individual and allowed to clot
for 30 min at room temperature. Subsequently, serum was
separated by centrifugation (3000 x g, 10 min), collected,
and stored at −80°C until analysis.
Induction of Endotoxemia
Male Wistar rats were implanted with catheters (SAI Infusion
Technologies, USA) into the jugular vein and after a two-day
recovery period they were administered with LPS dissolved in
saline at a dose of 1 mg kg −1 into the tail vein simultaneously
with one of the investigated compounds. GRMS-55 and roli-
pram were dissolved in vehicle composed of 10% DMSO in
saline and given at doses of 20 and 5 mg kg−1, respectively,
while (±)-LSF and PTX were dissolved in saline and were
administered at two doses of 40 and 80 mg kg−1. The doses
of the compounds were selected based on the literature data
or results of our previous experiments. Each control group
received LPS at the same IV dose and an appropriate volume
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of corresponding vehicle. Blood samples were collected via
catheters into polypropylene heparinized snap-cap tubes at
0, 15, 30, 60, 90, 120, and 180 min following (±)-LSF and
PTX dosing and at 30, 60, 90, 120, and 180 min after
GRMS-55 and rolipram administration and centrifuged at
3000 x g for 10 min. The plasma samples were collected
and stored at −80°C until analysis.
Induction of Arthritis
The emulsion of collagen was prepared according to the
Protocol for the Successful Induction of Collagen-Induced Arthritis
(CIA) in Rats (Chondrex Inc., 2015). Porcine type II collagen
dissolved in 0.05M acetic acid was emulsified with incomplete
Freund’s adiuvant (Sigma Aldrich, Germany) using an Omni
TH Homogenizer (Omni International, Inc., USA) consisting
of a blade with 5 mm diameter. The collagen solution was
previously mixed with IFA at a low speed for 1 min and then
at the highest speed for 2 min. Then emulsion was being
cooled for 5 min in an ice water bath. The emulsification
process was repeated 3 times to obtain a stiff emulsion. The
emulsion was then transferred into a Hamilton glass syringe,
kept at 4°C, and used within 2 h.
At a day 0 of the experiment animals were subcutane-
ously (SC) injected at the base of the tail with 200 μL of the
emulsion using a 27 gauge × 5/8″ needle and Hamilton
syringe. At day 7 after the initial immunization, a booster
injection with 100 μL of emulsion was performed. Ninety
% of rats developed symptoms of disease (paw swelling
>150% of day 0) at day 20 of the experiment. At this
day, diseased animals were randomly divided into five
groups (n = 6). Two investigated groups received IP
GRMS-55 at a dose of 50 mg kg−1 or rolipram at a dose
of 10 mg kg−1 once daily, dissolved in a vehicle composed
of 90/10 (v/v) of PEG 400 and DMSO. One investigated
group received (±)-LSF dissolved in saline at an SC dose of
80 mg kg−1 once daily. The corresponding control groups
were administered with appropriate volumes of vehicles IP
or SC. At day 40 animals were sacrificed. Hind paws of
rats were taken and immersed into 4% buffered formalin
solution for a subsequent histological analysis. Blood sam-
ples were collected and allowed to clot for 20 min and then
centrifuged at 2000 x g for 15 min. Serum samples were
collected and frozen at -80°C.
Measurement of Edema
Paw edema of arthritic rats was assessed as swelling of the
rat hind paws. Measurements of paws were performed us-
ing a digital caliper according to the procedure described
by Earp et al. (18). Each hind leg was measured at two
sections, i.e., paw and ankle, and each section was mea-
sured at two places (side-to-side and top-to-bottom). The
area of each section (elliptical in shape) was calculated from
the following equation:
Area ¼ π  a  b
4
ð2Þ
where (a) is side-to-side diameter of the ellipse and (b) is
top-to-bottom diameter of the ellipse. Paw and ankle sec-
tion areas of each leg were subsequently added to obtain
one overall measure for the rat hind paw (Areaoverall). Each
of these measures was normalized to the same hind paw
area measured at day 0 of the experiment (Areazero) to re-
duce variation in the disease progression resulting from
differences in paw size of each rat. Relative paw swelling




Paw size was measured at days 0, 5, 7, 11, 15, 18, 20, 22,
26, 30, 33, and 36 after the first immunization.
Histological Evaluation
The morphological studies were performed with the imaging
CellSens Dimention (Olympus) software. Osteoarthritis histo-
pathology was assessed based on the symptoms associated with
synovial inflammation, chondropathy, and subchondral oste-
oarthritis. Synovitis index estimation involved synovial inflam-
mation, synovial lining thickness, dense of cellularity, and
presence of perivascular lymphoid aggregates, where normal
synovium (score 0) is defined as thin linning with sparse cellu-
lar distribution and no/few inflammatory cells, mild andmod-
erate synovial inflammation (score 1 to 2) indicate thickness of
linning with dense cellularity with inflammatory cells, and
severe inflammation (score 3) means hypervascular synovitis
containing lymphoid aggregates. Two aspects of chondrop-
athy were graded: surface integrity and chondrocyte yielding
score 0 for normal morphology to score 3 for chondral lesion
with chondrocyte hypercellurarity and/or cloning, and com-
plete cartilage surface integrity loss. Subchondral plate thick-
ening, bone trabeculae deterioration, bone marrow lesion
(bone pseudocysts - cavitary lesion formation) associated with
fibrovascular replacement of marrow spaces were accounted
for subchondral osteoarthritis with grading score from 0 to 3
in severe lesion. The sample preparation procedure for histo-
logical evaluation is described in the supplementary materials.
Pharmacokinetic Studies
Pharmacokinetics of the studied compounds was investigated
in female Lewis rats following IV and IP administration of
GRMS-55 at doses of 20 and 40 mg kg−1, IV and SC ad-
ministration of (±)-LSF at doses of 40 and 80 mg kg−1, and IP
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administration of rolipram at a dose of 10 mg kg−1. In addi-
tion, pharmacokinetics of GRMS-55 and rolipram was stud-
ied following IV administration to male Wistar rats. GRMS-
55 was administered at a dose of 20 mg kg−1 and rolipram at
a dose of 5 mg kg−1. The same vehicles as these in pharma-
codynamic studies for each compound and route of adminis-
tration were used. Rats were implanted with catheters into
the jugular vein and after a two-day period they were admin-
istered with the investigated compounds by the listed above
routes of administration. Blood samples were collected from
the catheters to heparinized tubes at 5, 15, 30, 60, 90, and
120 min following (±)-LSF or GRMS-55 dosing and at 10,
20, 40, 80, 120, 160, and 220 min following rolipram admin-
istration to female Lewis rats. In turn, samples from male
Wistar rats were collected at 5, 15, 30, 60, 90, and 120 min
following GRMS-55 administration and 10, 20, 40, 80, and
120 min after rolipram dosing. Samples were subsequently
centrifuged at 3000 × g for 10 min. Plasma was stored at
−80°C until analysis.
Analytical Methods
To analyze levels of (±)-LSF and its metabolite PTX in plasma
of rats, the method described earlier was used (9). To deter-
mine GRMS-55 and rolipram concentrations in rat plasma,
HPLC methods with UV detection were developed. A de-
tailed description of these methods has been provided in the
supplementary materials. The calibration curve of GRMS-55
was linear at the range of 0.050–20 and for rolipram at the
range of 0.020–20 mg L−1.
TNF-α levels in LPS-stimulated rat blood in vitro and in rat
plasma samples from the in vivo studies were analyzed by the
Rat TNF-α Quantikine ELISA Immunoassay Kit (R&D
Systems, USA) according to the manufacturer’s instructions.
The assay was linear at the range of 12.5–800 pg mL−1.
Levels of TNF-α in mice serum were measured by ELISA
Kits for Tumor Necrosis Factor Alpha (Cloud-Clone Corp.,
USA). This assay was linear at the range of 15.6–
1000 pg mL−1. Absorbance was measured at 450 nm using
a POLARstar Omega multi-mode microplate reader (BMG
LABTECH, Germany).
Serum asparagine transaminase (AST) and alanine trans-
aminase (ALT) activity was analyzed using the chemistry an-
alyzer BS-800 (Shenzhen Mindray Bio-medical Electronics
Co. ltd, China).
Pharmacokinetic, PK/PD, and PK/PD/DIS Progression
Modeling
Firstly, the concentration-time data collected for each individ-
ual compound from one of the investigated rat strains (Wistar
or Lewis) were subjected to a non-compartmental analysis
(NCA). Subsequently, pharmacokinetic models were
developed for each investigated compound and strain of rat.
One- and two- compartment models with linear or non-linear
elimination were tested. In the case of (±)-LSF administration,
the existence of interconversion phenomenon between (±)-
LSF and PTX, which was also observed in our previous stud-
ies (9), was taken into account during model development.
The final models were chosen based on the goodness-of-fit
criteria, such as Akaike Information Criterion (AIC),
Schwarz Bayesian Criterion (SBC), weighted sum of squared
residuals (WSSR), a visual inspection of fitting, and precision
of estimated parameters expressed as coefficients of variation
% (CVs%). NCA analysis was performed in Phoenix
WinNonlin v. 7.0 (Pharsight Corp., a Certara Company,
Princeton, New Jersey). Pharmacokinetic model parameters
were estimated in ADAPT 5 software (BMSR, Los Angeles,
CA) using the weighted least squares algorithm. Fraction of
the dose absorbed (F) following an extravascular (EV) admin-
istration was calculated according to the Eq. 4:
F ¼ AUC0−t EVð Þ  DIV
AUC0−t IVð Þ  DEV
ð4Þ
where AUC0-t is the area under concentration versus time curve
from 0 to the last measured point and D is dose.
PK/PD and PK/PD/DIS progression models were devel-
oped considering the mechanism of action of the investigated
compounds, the mechanisms of disease progression in the case
of CIA, and the subsequent stages leading to TNF-α release in
the case of LPS-induced endotoxemia. Various numbers of
transit compartments were tested during development of the
models, and the final models were chosen based on the
goodness-of-fit criteria, such as AIC, SBC, a visual inspection
of the fitting, and parameter precision. Estimated values of
pharmacokinetic parameters were fixed during PK/PD and
PK/PD/DIS progression model fitting procedures. No influ-
ence of experimentally induced diseases (RA and LPS-induced
endotoxemia) on the values of pharmacokinetic parameters of
each investigated compound was found, as concentrations of
the test compounds in blood collected from diseased rats were
close to those predicted by the pharmacokinetic models devel-
oped in this study using healthy animals (data not shown).
Pharmacokinetic parameters of (±)-LSF and PTX in male
Wistar rats challenged with IV dose of 1 mg kg−1 of LPS were
taken from our previous study (9). PK/PD and PK/PD/DIS
progression modeling were performed in ADAPT 5 software
using the weighted least squares algorithm.
PK/PD Model of PDE Inhibitors in Endotoxemic Rats
In the LPS-induced endotoxemia model, TNF-α concentra-
tions were measured following IV administration of both (±)-
LSF and its metabolite – PTX. As following administration of
(±)-LSF or PTX to rats and other species both of these
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compounds occur simultaneously in plasma of an individual,
the interaction PK/PD model was used to estimate pharma-
codynamic parameters, including IC50 values, for each of
these compounds. An additive interaction between (±)-LSF
and PTX was assumed in the PK/PD model based on the
results of the recent study, where this type of interaction was
found between these compounds as modulators of cAMP
levels (9). To study the influence of GRMS-55 and rolipram
on TNF-α levels in this model, two other experiments with
independent control groups were performed. Therefore, as a
result of PK/PD analysis, three sets of pharmacodynamic
parameters were obtained based on the data from the three
individual experiments.
A structure of the developed PK/PD model for TNF-α
inhibitory effect of studied compounds is illustrated in Fig. 1a.
The applied model is a modified indirect response model
(19) with implemented transit compartments (T1-T4) that de-
scribe the delay of the observed pharmacodynamic response.
In this scheme τ is the mean transit time, kin is the time limited
(from 0 to tlag) zero-order rate constant of production of a
TNF-α precursor (e.g., TNF-α mRNA). Different numbers
of transit compartments were tested during the model devel-
opment, but the best fit was observed using four transit com-
partments. Pharmacokinetic parameters of GRMS-55 (Eq. 5)
and rolipram (Eqs. 6 and 7) inmaleWistar rats were estimated
prior to the PK/PD analysis by solving the following differen-
tial equations:
V GRMS−55  dCGRMS−55
dt
¼ −CLt GRMS−55ð Þ  CGRMS−55 ð5Þ
V 1 ROLð Þ 
dC1 ROLð Þ
dt
¼ − CLt ROLð Þ þ CLd ROLð Þ
   C1 ROLð Þ þ CLd ROLð Þ  C2 ROLð Þ
ð6Þ
V 2 ROLð Þ 
dC2 ROLð Þ
dt
¼ CLd ROLð Þ  C1 ROLð Þ−C2 ROLð Þ
  ð7Þ
where CGRMS-55 and C1(ROL) are concentrations of each com-
pound in the central compartments, while C2(ROL) is rolipram
concentration in the peripheral compartment. Clt(GRMS-55) and
Clt(ROL) are the total clearances, and VGRMS-55 and V1(ROL) are
Fig. 1 Schematic representation of the proposed PK/PDmodel to describe changes in TNF-α plasma levels inmaleWistar rats with LPS-induced endotoxemia a
and PK/PD/DIS model of arthritis progression in female Lewis rats b treated with the studied compounds; Prec are the hypothetical precursors of TNF-α
production a or relative paw edema b in the precursor compartments, Imax is the maximal inhibitory effect of each compound, Cp is a plasma concentration of the
test compound (GRMS-55, (±)-LSF, rolipram, and additionally PTX in the case of endotoxemic rats), IC50 is the concentration of each compound that produce
50% of Imax, Paw is a relative paw swelling, τ is the mean transit time, kin is the zero-order rate constant of production of Prec, while kin(t) is the zero-order
production component of Prec, kdeg is the first-order rate constant of kin(t) reduction, T1-T4 are precursors of TNF-α production a or relative paw edema b in
subsequent transit compartments, kout is the first-order rate constant of Prec degradation, and kgrow is the zero-order rate constant accounting for natural paw
growth.
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volumes of central compartments for each compound, while
V2(ROL) is the volume of peripheral compartment for rolipram.
Cld(ROL) is the distribution clearance of rolipram.
Pharmacodynamic parameters of the proposed PK/PD




¼ kin  1−
I maxPTX  CPTX
IC50PTX þ CPTX
 
 1− I maxLSF  CLSF
IC50LSF þ CLSF
 






¼ kin  1−
I max  Cp
IC50 þ Cp
 






¼ Prec−T 1ð Þ  1τ ; T 1 0ð Þ ¼ R0 ð10Þ
dT nþ1
dt
¼ T n−T nþ1ð Þ  1τ ; T nþ1 0ð Þ ¼ R0; n ¼ 1∼3 ð11Þ
dCTNF
dt
¼ T 4−CTNFð Þ  1τ ; CTNF 0ð Þ ¼ R0 ð12Þ
The Eq. 8 was used when fitting the model to the data from
the experiment on PTX and (±)-LSF, while Eq. 9 in the case
of GRMS-55 or rolipram. Imax, ImaxPTX, and ImaxLSF are the
maximal inhibitory effects of each compound on the produc-
tion rate constant (kin), Cp, CPTX, and CLSF are plasma concen-
trations of the compounds, and IC50, IC50PTX and IC50LSF are
concentrations of each compound that produce 50% of Imax,
Prec is a concentration of precursor in the precursor compart-
ment, Tn is a concentration of transmitter in the n
th transit
compartment, CTNF is a concentration of TNF-α in rat plas-
ma, R0 is the basal plasma concentration of TNF-α in healthy
rats equal to 12.7 pg mL−1, calculated as the average of con-
centrations measured in samples collected from 4 healthy
male Wistar rats. All Imax values were fixed to 1.
PK/PD/Arthritis Progression Modeling of PDE Inhibitors
In the pharmacokinetic study, the female Lewis rats were ad-
ministered with (±)-LSF by IV and SC routes, GRMS-55 by
IV and IP routes, and rolipram by IP route. The route of (±)-
LSF administration was selected based on the results of our
recent study, where SC route of administration was recog-
nized as the most preferential for this compound (20). The
concentration-time data for each of the investigated com-
pounds were simultaneously fitted to obtain a single set of
pharmacokinetic parameters. Schematic representations of
the applied pharmacokinetic models are presented in Fig. 2.
Pharmacokinetic parameters of GRMS-55 (Eqs. 13,
14, and 15), rolipram (Eqs. 16 and 17), and LSF (Eqs.
18, 19, and 20) in female Lewis rats have been estimated
prior to the PK/PD analysis by solving the following dif-
ferential equations:
V 1 GRMS−55ð Þ 
dC1 GRMS−55ð Þ
dt
¼ − CLt GRMS−55ð Þ þ CLd GRMS−55ð Þ
   C1 GRMS−55ð Þ




¼ −ka GRMS−55ð Þ  AGRMS−55 ð14Þ
V 2 GRMS−55ð Þ 
dC2 GRMS−55ð Þ
dt
¼ CLd GRMS−55ð Þ  C1 GRMS−55ð Þ−C2 GRMS−55ð Þ
 
ð15Þ
V ROL  dCROL
dt
¼ −CLt ROLð Þ  CROL þ ka ROLð Þ  AROL ð16Þ
dAROL
dt
¼ −ka ROLð Þ  AROL ð17Þ
dXLSF
dt
¼ −kd  XLSF þ ka LSFð Þ  ALSF þ kconv  XPTXm ð18Þ
dXPTXm
dt
¼ −kem  XPTXm þ kd  XLSF−kconv  XPTXm ð19Þ
dALSF
dt
¼ −ka LSFð Þ  ALSF ð20Þ
where XLSF is an amount of (±)-LSF in the central compartment
and XPTXm is an amount of PTX in the metabolite compartment
divided by the fraction metabolized (fm). Concentrations of (±)-LSF
and PTX in these compartments are equal to XLSF/VLSF and
XPTXm· fm/VPTXm, respectively. The remaining symbols and param-
eters have been explained and defined in Fig. 2 and Table II.
To describe changes in paw size in rats with CIA, several
PK/PD/DIS progression models described in the literature
were tested, including the modified indirect response model
developed by Earp et al. (18) and the transduction-based feed-
back model (21), but the model developed in this study dem-
onstrated the best fitting to the experimental data collected. In
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this model, the effect of PDE inhibitors was described by the
type I indirect response model with signal transduction, which
incorporates an inhibitory effect on the production of a pre-
cursor. A precursor is not defined, but it may be a certain
cytokine, such as TNF-α or its mRNA, as PDE inhibitors
are recognized inhibitors of cytokine synthesis and release. A
schematic representation of the proposed PK/PD/DIS pro-
gression model of CIA is illustrated in Fig. 1b. From this fig-
ure, the developedmodel is a modified type I indirect response
model with the implemented production component repre-
sented by the rate kin(t), which is a function of time that is
reduced by the loss of production first-order rate constant (k-
deg), representing a linear decline in the variable kin(t) and
accounts for the natural remission of arthritis after disease
onset. kgrow is the zero-order rate constant of a natural paw
growth, τ is the mean transit time, kout is the first-order disap-
pearance rate constant of the precursor of paw edema. Transit
compartments (T1-T4) have been used in the model to de-
scribe a signal transduction leading to paw swelling.
The values of pharmacodynamic parameters of PK/PD/
DIS model of arthritis progression were estimated by solving




0; t < tonset ; Prec 0ð Þ ¼ 1
kin tð Þ  1− Imax  Cp
IC50 þ Cp
 






¼ −kdeg  kin; kin 0ð Þ ¼ k0in ð22Þ
dT 1
dt
¼ Prec−T 1ð Þ  1τ ; T 1 0ð Þ ¼ 1 ð23Þ
dT nþ1
dt




¼ T 4−Pawð Þ  1τ þ kgrow; Paw 0ð Þ ¼ 1 ð25Þ
Prec is a hypothetical precursor of relative paw edema in the
precursor compartment, tonset is the delay in production of the
precursor accounting for the delay in disease onset, and kin(0) is
the initial condition of kin(t) variable.
Statistical Analysis
All statistical calculations were performed in IBM SPSS
Statistics 24 (IBM Corp., USA) or STATISTICA 13 (Tibco
Software Inc., USA). Analyses of parametric data were per-
formed using the Student’s t test or a one-way analysis of
variance (ANOVA) followed by an appropriate post-hoc test
in the case of more than 2 groups tested. Non-parametric data
were compared using Mann-Whitney U or Kruskal–Wallis
tests in the case of more than 2 groups tested. P values less
than 0.05 were considered as statistically significant.
Fig. 2 Schematic representation of the pharmacokinetic models of (±)-LSF a,
GRMS-55 b, and rolipram c following IV and SC administration of (±)-LSF at
doses of 40 and 80mg kg-1, IV and IP administration of GRMS-55 at doses of 20
and 40 mg kg-1, respectively, and IP administration of rolipram at a dose of
10 mg kg−1 to female Lewis rats; AGRMS-55, ALSF, and AROL are amounts of each
compound in the absorption compartments; F(GRMS-55), F(LSF), and F(ROL) are the
fractions absorbed following EV administration of GRMS-55, (±)-LSF, and roli-
pram, respectively; ka(ROL), ka(GRMS-55), and ka(LSF) are the first-order absorption
rate constants of each compound following EV dosing; C1(GRMS-55), CLSF, CROL,
and CPTXm are plasma concentrations of GRMS-55, (±)-LSF, rolipram, and PTX
as a metabolite, while C2(GRMS-55) is the concentration of GRMS-55 in the
peripheral compartment; V1(GRMS-55), VLSF, VROL, and VPTXm are volumes of cen-
tral compartments for each compound, while V2(GRMS-55) is the volume of
peripheral compartment for GRMS-55; Cld(GRMS-55) is the distribution clearance
of GRMS-55; kd is the first-order rate constant for disappearance of (±)-LSF; fm is
a fraction of (±)-LSF metabolized; kconv is the first-order rate constant of con-
version of PTX to (±)-LSF; Clt(GRMS-55) and Clt(ROL) are the total clearances, kem is
the first-order rate constant of PTX elimination.
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RESULTS
PDE Assay
Inhibitory activities of the investigated and reference com-
pounds against various hrPDEs were examined and the values
of IC50, Imax, and γ parameters of the studied inhibitors have
been listed in Table 1.
From this table, GRMS-55 exhibited a strong inhibitory ac-
tivity (comparable to that of reference compounds) against
hrPDE1B and hrPDE7A. In addition, a moderate activity of
this compound on hrPDE3A and hrPDE4B and a slight activity
against hrPDE10A were observed. GRMS-55 did not inhibit
hrPDE2A, hrPDE4D, and hrPDE5A at the range of concen-
trations tested. On the other hand, (±)-LSF displayed a moder-
ate inhibitory activity against hrPDE1B and hrPDE4B, and only
a slight activity was noted in the cases of hrPDE2A and
hrPDE3A. The reference compounds, being selective or prefer-
ential inhibitors of individual isoenzymes, exhibited micromolar
activity, while papaverine and milrinone demonstrated IC50 val-
ues below 1 μM on hrPDE10A and hrPDE3A, respectively.
Both GRMS-55 and (±)-LSF demonstrated an inhibitory activ-
ity against hrPDE4B, which is crucial for achieving the anti-
inflammatory and immunomodulatory effects (1). However,
they were considerably weaker than the reference compound
– rolipram, i.e., 24 times in the case of GRMS-55 and 45 times
for (±)-LSF. Nevertheless, none of them demonstrated activity
against hrPDE4D at a range of concentrations tested, inhibition
of which is supposed to be associated with the occurrence of
nausea and vomiting. In contrast, rolipram exhibited a strong
inhibitory activity on hrPDE4D. The abovementioned unde-
sired symptoms are frequently observed side effects following
administration of PDE4 inhibitors (15). The observed selectivity
of the investigated compounds in relation to PDE4B vs. PDE4D
may be essential for their suitability for therapeutic applications.
The representative inhibition graphs illustrating inhibitory prop-
erties and fittings of the pharmacodynamic model to the data of
each investigated and reference compound have been placed in
the supplementary materials (Fig. 1S).
TNF-α Inhibition In Vitro
The results of in vitro study of TNF-α release inhibition in whole
rat blood stimulated with LPS have been illustrated in Fig. 3.
The graph shows that both PTX and (±)-LSF significantly
and with similar potency reduced levels of TNF-α, while
GRMS-55 did not exhibit activity in this test compared to
the LPS-treated control. Rolipram, a potent PDE4 inhibitor,
Table 1 Inhibitory Activities of the Studied Compounds Against Different hrPDEs, Expressed as Estimated Values of IC50, Imax, and γ Parameters




















































































a data already published (9,16)
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at a concentration of 50 μM completely reduced the levels of
TNF-α in LPS-stimulated rat blood compared to the control
group. Moreover, the activity of this compound was signifi-
cantly higher than those of PTX and (±)-LSF. It is worth
noting that (±)-LSF and PTX inhibited TNF-α release in a
dose-dependent manner.
Pharmacokinetics
(±)-LSF demonstrated a linear pharmacokinetics in female
Lewis rats, as a 1-compartment model with a metabolite com-
partment and linear elimination well described the concentra-
tion vs. time profiles of this compound and PTX as a metab-
olite. GRMS-55 displayed a biphasic, linear pharmacokinetics
corresponding to a 2-compartment model, while the
concentration-time data obtained after IP administration of
rolipram were best described by a 1-compartment model. In
the pharmacokinetic experiments performed in male Wistar
rats, both GRMS-55 and rolipram were administered by IV
route. The concentration-time data from the study on
GRMS-55 were best captured by a 1-compartment pharma-
cokinetic model, while rolipram displayed a biphasic pharma-
cokinetics in male Wistar rats. Pharmacokinetic models
employed in this study were simultaneously fitted to the data
to obtain a single set of pharmacokinetic parameters for each
investigated compound and rat strain.
As illustrated in the graphs (Fig. 4a-c), the model predicted
concentration vs. time profiles of the investigated compounds
in female Lewist rats fairly well captured their measured levels
in rat plasma. The estimated by the models values of pharma-
cokinetic parameters are collected in Table II.
A flip-flop pharmacokinetics was observed following SC
administration of (±)-LSF. Thus, despite the high value of kd
constant, the rate of (±)-LSF elimination was limited by 6.6
times lower rate of its absorption, and therefore, the plasma
terminal half-life was equal to 23 min. The values of GRMS-
55 and rolipram elimination rate constants estimated by the
models were comparable and, in consequence, half-life values
calculated as ln2·V1/Clt were similar and equal to 21 and
30 min, respectively. Calculated from the Eqs. 4 fraction of
the dose absorbed was 23% following IP administration of
GRMS-55 and 95% following SC administration of (±)-
LSF. In the case of (±)-LSF this value was similar to that
observed in male Wistar rats, confirming the earlier observa-
tion that SC route is the most preferential EV route of admin-
istration of this compound (20). The volume of distribution of
GRMS-55 was considerably larger (~2.7 times) and the elim-
ination rate constant of this compound was approx. 2 times
lower compared to those of rolipram. In contrast to the ex-
periment in female Lewis rats, the concentration-time data
obtained following the GRMS-55 dosing to male Wistar rats
were better described by a 1-compartment pharmacokinetic
model, while a 2-compartment model was more suitable to
capture the pharmacokinetic profile of rolipram (Fig. 4d).
Pharmacokinetics of (±)-LSF and PTX in male Wistar rats
has already been investigated in our recent study (9), so the
values of pharmacokinetic parameters of (±)-LSF and PTX
estimated in that study (Table 2) were used in further PK/PD
analysis of these compounds in the LPS-induced endotoxemia
model.
ConA-Induced Hepatitis
Figure 5 shows the results of experiment performed in BALB/
c mice, which were pre-treated with the investigated and ref-
erence PDE inhibitors or vehicle alone (control group) and
subsequently administered with IV dose of ConA.
The data presented in the bar charts indicate that rolipram
at a dose of 10 mg kg−1 as well as GRMS-55 at a dose of
50 mg kg−1 most potently inhibited TNF-α release (p< 0.01)
and significantly reduced (p< 0.01) the activities of transami-
nases in mice sera compared to the control group 8 h follow-
ing ConA administration. (±)-LSF, which is the weakest inhib-
itor of PDE4B and PDE7A out of the investigated com-
pounds, demonstrated only a moderate activity at a dose of
50 mg kg−1 significantly reducing TNF-α levels, however, it
failed to decrease the activities of transaminases. These results
indicate that selective inhibition of PDE4 is responsible for the
Fig. 3 Inhibition of LPS-induced
TNF-α release in whole rat blood
by the investigated and reference
compounds. Each value represents
the mean (±SD) % of the control
(vehicle + LPS) of four independent
cultures. ** p<0.001, * p<0.05
compared to the control group
(vehicle + LPS), using Tamhane’s
T2 multiple comparison parametric
test for unequal variance.
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observed anti-inflammatory and hepatoprotective effects in
ConA-induced hepatitis. Moreover, the PDE4B inhibition
seems to be mainly engaged in these activities and a blockage
of PDE4D is not required to achieve these effects.
LPS-Induced Endotoxemia
Figure 6a-d shows the mean observed and predicted by the
PK/PD model concentrations of TNF-α in plasma of rats
challenged with IV dose of LPS in the presence and absence
of the studied compounds.
From these graphs, TNF-α changes in rat plasma were
satisfactorily predicted by the proposed PK/PD model.
Pharmacodynamic parameters for each of the investigated
compounds are summarized in Table III.
From this table, the strongest activity was observed in the
case of rolipram, and it was ~3, ~16, and ~39 times higher
than those of GRMS-55, (±)-LSF, and PTX. PTX was con-
siderably weaker than (±)-LSF in inhibiting TNF-α release
in vivo as indicated by the relatively high IC50 value of PTX
estimated by the model. Thus, considering that rather low
levels of PTX are attained in plasma of rats administered with
(±)-LSF, it can be concluded that the influence of PTX on
TNF-α release after administration of (±)-LSF is minor.
Collagen-Induced Arthritis
This study was performed in two independent experiments
due to the fact that two different routes of administration of
compounds and vehicles in each experiment were used.
Model fittings of the relative paw swelling data from the three
treatment groups and two control groups are presented in
Fig. 6e and f. From these graphs, the applied PK/PD/DIS
model well described the changes of relative paw edema in all
investigated groups. There was observed a slight increase in
paw size during the first 13 days of the experiment
corresponding to a natural growth of a paw, and then a rapid
increase in a paw edema with the peak at ~20th day post the
first immunization. Subsequently, paw size began to decrease
gradually in all investigated groups. However, in the groups
treated with the investigated compounds the initial reduction
in paw edema was more rapid. At the last observation time
point, the relative paw swelling decreased by 35.2, 31.5, and
30.5% after rolipram, GRMS-55, and (±)-LSF administra-
tion, respectively. The values of pharmacodynamic and dis-
ease progression parameters are listed in Table IV.
From this table, the drug-independent parameter values,
i.e., kout, kdeg, tlag, kin(0), and τwere similar among all investigated
groups despite the fact of using different vehicles and routes of
Fig. 4 Mean (±SD) observed
(symbols) and predicted by the
models (lines) (±)-LSF and PTX,
GRMS-55, and rolipram plasma
concentrations following (±)-LSF a,
GRMS-55 b, or rolipram c admin-
istration to female Lewis rats and IV
administration of rolipram or
GRMS-55 to male Wistar rats (d)
(n=3–4).
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administration. The value of kgrow was calculated based on the
results of the previous study performed in Lewis rats (22) and
fixed during iteration process. Rolipram demonstrated the
highest inhibitory properties as indicated by the IC50 value,
which was the lowest among the tested compounds. GRMS-
55 exhibited ~26 and (±)-LSF ~100 times higher IC50 value
than rolipram. However, the observed differences in relative
paw swelling among the treatment groups were not different
statistically at any of the time points measured. TNF-α serum
levels in rats from groups treated with the investigated com-
pounds and vehicle alone measured at the end of the experi-
ment by ELISA were below the LOQ (12.5 pg mL−1).
Additional data obtained, such as time courses of the mean
relative body weights, clinical score values, and paw areas with
the results of statistical analysis were presented in supplemen-
tary materials (Fig. 2S).
Histological Evaluation
Histopathological assessment aimed to determine overall pat-
tern of injury and the scoring focused on a grade of synovial
inflammation and articular cartilage lesions associated with
subchondral bone injury. Animals in positive control group
(vehicle treated CIA rats) exhibited full range of pathological
symptoms, such as severe synovial inflammation, cartilage de-
generation revealed by its surface integrity loss, chondrocyte
alteration (loss or hypercellurarity and/or cloning), and sub-
chondral lesions: enormous subchondral plate thickening, tra-
beculae deterioration, bone marrow lesions (bone “pseudo-
cysts” - cavitary lesion forming) frequently associated with fi-
brovascular replacement of marrow spaces (Fig. 7).
Figure 7 shows that administration with all studied com-
pounds to CIA rats led to a significant amelioration of synovial
inflammation and concurrent articular cartilage and subchon-
dral bone remodeling in relation to the vehicle control, except
(±)-LSF in the case of subchondral osteoarthritis. Treatment
with rolipram led to a significant amelioration of these symp-
toms compared to vehicle control. The treatment with both
GRMS-55 and (±)-LSF induced a significant alleviation of
histopathological appearance of synovium compared to vehi-
cle treated animals. In particular, synovial linning became
thinner and cellularity of inflammatory cells sparse. After mul-
tiple administration of both GRMS-55 and (±)-LSF, chondri-
tis and subchondral osteoarthritis were attenuated compared
to vehicle control, except for (±)-LSF in the case of subchon-
dral arthritis. Rolipram was more potent than GRMS-55 in
alleviating subchondral osteoarthritis and more active than
(±)-LSF in ameliorating chondritis and subchondral osteoar-
thritis. In contrast to the vehicle control group, structural heal-
ing changes, such as regenerating articular cartilage in rats
treated with the tested compounds can be observed.
DISCUSSION
The aim of this study was to compare the pharmacological
activity of the two PDE inhibitors, namely GRMS-55 and (±)-
LSF.We demonstrated that PDE4B but not PDE4D blockage
is essential to obtain a therapeutic effect in animal models of
immune-mediated hepatitis, autoimmune rheumatoid arthri-
tis, and endotoxemia. This observation indicates that com-
pounds revealing strong to moderate PDE4B but not
Fig. 5 Inhibition of TNF-α secretion (a) and a decrease in ALT (b) and AST (c) activities in ConA-induced hepatitis in mice by the investigated and reference
compounds 8 h following ConA administration. Each value represents the mean (+SD) level of each biomarker in mice serum (n=6). * p< 0.05, ** p<0.01,
a one-way ANOVA with Tukey HSD post-hoc test.
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PDE4D inhibitory properties may constitute a better thera-
peutic option compared to pan-PDE4 inhibitors, which are
burdened with gastrointestinal adverse effects arising from
PDE4D inhibition. Furthermore, it has been indirectly dem-
onstrated that a PDE7A inhibitory component may reinforce
the therapeutic activity in animal models of immune-related
disorders, however, the observed therapeutic effect seems to
be mainly dependent on the potency of PDE4B inhibition.
Finally, we developed PK/PD and PK/PD/DIS progression
models, which may serve for further studies on anti-
inflammatory and immune-regulatory properties of PDE
inhibitors. Our results indicate that both GRMS-55 and (±)-
LSF are interesting compounds for future pre-clinical and
clinical studies on the treatment of immune-related disorders.
Due to the ubiquitous expression of different types and
subtypes of PDEs in the human body and their involvement
in a variety of signaling pathways, PDE inhibitors have
emerged as a large group of drugs for the treatment of various
disorders. However, despite the undeniable therapeutic po-
tential of these compounds, some PDE inhibitors are bur-
dened with certain adverse effects. For instance, potent
PDE3 inhibitors demonstrate a strong inotropic effect and
may induce life-threatening arrhythmias in people with heart
rhythm disorders (23). In turn, potent PDE10A inhibitors
Fig. 6 Mean (±SD) observed
(symbols) and predicted (lines)
based on the PK/PD model devel-
oped in this study plasma TNF-α
concentrations following a single IV
dose of (±)-LSF or PTX a and b,
GRMS-55 c, or rolipram d to male
Wistar rats with LPS-induced
endotoxemia (n=4); Time course
of mean (±SD) observed (symbols)
and predicted (lines) based on the
PK/PD/DIS progression model de-
veloped in this study relative paw
swelling following multiple adminis-
tration of rolipram or GRMS-55 e
and (±)-LSF f to female Lewis rats
with CIA (n= 6).
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have been shown to induce cataleptic-like effect in rodents (8).
However, in clinical trials somnolence was the most common-
ly observed adverse effect in this group of compounds. PDE4
inhibitors induce gastrointestinal adverse effects, such as nau-
sea and emesis. Therefore, they are often poorly tolerated by
patients. The results of pre-clinical studies indicate that
PDE4D inhibition is responsible for this type of adverse effects
(15). GRMS-55 demonstrated a moderate and (±)-LSF weak
activity against hrPDE3A, which indicates a limited possibility
of occurrence of the side effects resulting from the inhibition of
this type of PDE. Moreover, both compounds did not inhibit
hrPDE4D at the concentrations tested. GRMS-55 exhibited
only weak inhibitory properties against hrPDE10A. On the
other hand, both compounds inhibited hrPDE4B, which is at
least partially responsible for the therapeutic effect of these
compounds. In addition, GRMS-55 is a potent hrPDE7A
inhibitor. This feature may cause an additional anti-
inflammatory and/or immunomodulatory effect, as dual
PDE4/7 inhibitors demonstrated favorable properties com-
pared to selective PDE4 inhibitors in a number of pre-
clinical studies (2). These profiles of PDE inhibition of
GRMS-55 and (±)-LSF seem to be very preferential com-
pared to that of rolipram, which is a potent pan-selective
PDE4 inhibitor similarly inhibiting both PDE4B and
PDE4D subtypes. Due to the latter feature of this compound,
it induced nausea and emesis in clinical trials, and therefore,
despite the number of beneficial properties, it has not been
registered as a drug so far (6). The results of PDE inhibitory
activity assay performed in this study are in agreement with
the results obtained in earlier studies, where vinopocetine (24),
EHNA (25), milrinone (26), rolipram, BRL-50481 (27), and
papaverine (8) demonstrated similar IC50 values against
corresponding types of PDE. Only in the case of zaprinast,
the estimated IC50 value was higher than that observed in the
previous studies (28), probably due to the relatively high con-
centration of cGMP (5 μM) which was required in the PDE
assay used in this study.
In the in vitro TNF-α inhibition assay, rolipram occurred to
be the most potent molecule, even at a concentration of
50 μM. In contrast, GRMS-55 at the levels of 50 and
250 μM failed to inhibit TNF-α release compared to the con-
trol wells, while both were active in vivo. The possible reasons
for the observed discrepancy may be a limited solubility of
GRMS-55 in the assay medium or an interaction of GRMS-
55 with other, than present in blood monocytes and lympho-
cytes, immune cells responsible for TNF-α release upon stim-
uli in vivo. For example, Kupffer cells or alveolar macrophages
may release TNF-α upon LPS stimulation (29,30) and at the
Table III Pharmacodynamic Parameters Estimated Using the PK/PD Model Presented in Fig. 1a Following IV Administration of GRMS-55, (±)-LSF, PTX, or
Rolipram to Rats Challenged with LPS
GRMS-55 Rolipram (±)-LSF PTX
Parameter Brief description Final estimate (CV%) Final estimate (CV%) Final estimate (CV%)
kout (min
−1) Degradation of TNF-α precursor rate constant 0.059 (41.5) 0.031 (10.2) 0.034 (15.9)
kin (ng L
−1 min−1) Production of TNF-α precursor rate constant 0.809 (18.5) 1.83 (23.31) 0.827 (16.16)
tlag (min) Time of the precursor production 57.1 (19.5) 48.6 (15.1) 60.0 (13.4)
τ (min) Mean transit time 8.0 (27.7) 12.0 (10.2) 7.3 (15.1)
IC50 (mg L
−1) Concentration of compound producing 50% of Imax 1.06 (77.3) 0.36 (18.9) 5.80 (19.7) 14.00 (32.2)
Imax Maximal inhibitory activity 1
a 1a 1a 1a
a fixed during fitting procedure
Table IV Parameters Estimated Using the PK/PD/DIS Arthritis Progression Model Presented in Fig. 1b FollowingMultiple Administration of GRMS-55, (±)-LSF,
or Rolipram to Rats with Experimentally Induced Arthritis
(±)-LSF GRMS-55 Rolipram
Parameter Brief description Final estimate (CV%) Final estimate (CV%)
kout (day
-1) Degradation of precursor rate constant 0.258 (1.7) 0.281 (1.6)
kdeg (day
-1) Loss of production rate constant 0.0133 (13.4) 0.0127 (15.4)
tonset (day) Time of disease onset 12.6 (3.9) 13.3 (2.3)
τ (day) Mean transit time 0.371 (19.7) 0.257 (16.8)
IC50 (mg L
-1) Concentration producing 50% of maximal inhibition 1.06 (77.3) 0.26 (45.0) 0.01 (75.5)
kgrow (day
-1) Natural growth rate constant 0.004a 0.004a 0.004a
kin(0) (day
-1) Initial value of precursor production variable 0.498 (1.1) 0.521 (1.5) 0.523 (1.2)
Imax Maximal inhibitory potency 1
b 1b 1b
a calculated based on the data from (22); b fixed during fitting procedure
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same time they may be more susceptible to anti-inflammatory
activity of some PDE inhibitors. The observed phenomenon,
although not elucidated yet, indicates some limitations of this
widely used in vitro test for the screening of anti-inflammatory
compounds. On the other hand, (±)-LSF and its metabolite –
PTX exhibited comparable, dose-dependent inhibitory prop-
erties. However, even at a concentration of 250 μM these
compounds acted significantly weaker than rolipram at a low-
er concentration. These results are in agreement with the ear-
lier study on PDE inhibitors, where rolipram and other PDE4
inhibitor RP73401 (IC50PDE4= 1 nM) exhibited a dose depen-
dent activity in LPS-stimulated murine macrophages and hu-
man PBMC. The IC50 values were 2.7 nM for RP73401 and
59.3 nM for rolipram in murine macrophage cell line and
Fig. 7 Histological examination of
ankle cross-sections from arthritic
rats treated with vehicle only (posi-
tive control) a, rats administered
with GRMS-55 b, animals treated
with (±)-LSF c, rats administered
with rolipram d, and healthy animals
not subjected to the immunization
procedure e. On the left side, a
low-power magnified view (objec-
tive lens 4x) of ankle joints is pre-
sented. On the right side, a high-
power magnified view (objective
lens 40x) of boxed area indicated on
the left is shown. Synovitis and leu-
cocytes infiltrating into synovial fluid
spaces and synovium are shown as
asterisks. Articular cartilage degen-
eration is depicted as arrow heads.
Arrows represent subchondral plate
thickening, whereas arrows with
tails indicate trabeculae deteriora-
tion, cavitary lesions, and fibrovas-
cular replacement of marrow
spaces. Ellipses match regenerating
articular cartilage. f Mean (±) stan-
dard error histological scores for
three categories: synovitis, chondri-
tis, and subchondral osteoarthritis
assessed in ankle cross-sections
from rats with CIA treated with ve-
hicle only and the investigated
compounds; *p< 0.05, **p<
0.01– compared to the vehicle
control group, #p< 0.05 – com-
pared to the rolipram treated group
(n= 4) Kruskal–Wallis with Dunn’s
multiple comparison post-hoc test.
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3.3 nM for RP73401 in PBMC. Furthermore, PTX also sig-
nificantly inhibited TNF-α production in that study in
RAW263.7 cells at concentrations of 500 and 1000 μM (31).
Moreover, a correlation between suppressive function of
PDE4 inhibitors on antigen-stimulated T cell proliferation
and their inhibitory activity against PDE4A and PDE4B sub-
types was observed, while no correlation was noted with re-
spect to a PDE4D inhibitory activity. Similarly, the potency of
inhibition of LPS-induced TNF-α release from human mono-
cytes was significantly correlated with the inhibition of PDE4A
(r = 0.903, P= 0.001) and PDE4B (r = 0.891, P = 0.001). In
contrast, a correlation between the inhibitory activity on
TNF-α release and PDE4D was not statistically significant
(r = 0.600, P= 0.073) (1), which implies that an inhibition of
PDE4B but not PDE4D is crucial to obtain the anti-
inflammatory effect of PDE4 inhibitors.
ConA-induced hepatitis in mice is a widely used model of
T cell mediated liver injury, which in many aspects closely
resembles AIH – a severe human disorder that often leads to
liver fibrosis and, in consequence, to liver failure. Therefore,
this model has been frequently utilized in the search for new
drugs and treatment options for AIH (32). In the course of
ConA-induced hepatitis, similarly to AIH, T-cells and a wide
range of cytokines are engaged in the disease process and
serum transaminase activity is dramatically increased. The
current conventional treatment of AIH is based on the admin-
istration of a corticosteroid in combination with azathioprine.
Usually it must be continued lifelong, despite the fact of severe
adverse effects of these drugs that often manifest. But even if
treatment is implemented, some of the patients do not achieve
complete remission. In these cases, progressive fibrosis of the
liver leads to the liver failure, when the only remaining treat-
ment option is the organ transplantation. TNF-α is considered
as one of the crucial mediators of liver damage in AIH, thus,
anti-TNF-α biological drugs have been used in difficult-to-
treat patients suffering from this disorder (11). PDE inhibitors
have been earlier successfully tested in the ConA-induced hep-
atitis model inmice. A selective PDE4 inhibitor – rolipram has
been shown to ameliorate the outcomes of this disease. It
decreased TNF-α, IFN-γ, and IL-4 levels and increased con-
centrations of an anti-inflammatory cytokine, IL-10. It also
reduced plasma ALT and AST activities. Motapizone, a se-
lective PDE3 inhibitor, exhibited similar properties to those of
rolipram. However, it did not change IL-4 levels significantly
at a range of doses tested (0.1–10 mg kg−1) (33). In the present
study, similar observations were made as rolipram reduced
levels of TNF-α and decreased AST and ALT activities in
serum ofmice. In another study, a PDE inhibitor with a strong
activity against PDE7A (IC50= 9 nM) has been investigated in
the ConA-induced hepatitis model and it decreased ALT ac-
tivity and TNF-α levels (34). Thus, it can be concluded that
the observed effects of PDE inhibitors in ConA-induced hep-
atitis arise both from the inhibition of PDE4B and PDE7A.
Moreover, as it has been shown in the previous studies, PDE3
inhibition can additionally support this effect. As expected,
GRMS-55, which is a potent hrPDE7A and a moderate
hrPDE3A/4B inhibitor, exhibited a strong therapeutic effect
in ConA-induced hepatitis. On the other hand, (±)-LSF,
which is a non-selective PDE inhibitor with weaker PDE3A,
PDE4B, and PDE7A inhibitory properties, failed to signifi-
cantly decrease the activity of transaminases at an IP dose of
50 mg kg−1, however, it decreased TNF-α concentration in
mice serum. The observed discrepancy may arise from an
additional activity of (±)-LSF, which demonstrates STAT4
inhibitory properties (35). It has been shown, STAT4 deficient
mice exhibited an increased susceptibility to ConA in ConA-
induced hepatitis (36). Thus, an inhibition of STAT4 by (±)-
LSF could have led to the exacerbation of the disease.
Pharmacokinetics of (±)-LSF has been already deeply in-
vestigated in rats (20) but also in other species. The results of
our experiments are in agreement with those from earlier
studies on this compound in rats. Some observed differences
could have arisen from the use of different strains and sexes
of rats. Female Lewis rats displayed 3.3 times lower value of
volume of (±)-LSF distribution compared to male Wistar
rats. Moreover, in the earlier studies in male rodents, an
existence of nonlinearity in the process of elimination of
(±)-LSF was observed, while in the case of female Lewis rats
the elimination was linear. A high bioavailability following
SC dosing was confirmed in this study, indicating that this
route of administration is the most appropriate for pre-
clinical studies on (±)-LSF (20). In the present study, roli-
pram exhibited a fast absorption following IP administration
and a quite fast elimination, as the elimination half-life of
this compound was equal to 11 min in the case of male and
30 min in female rats. The results of earlier study indicate
that this compound has the elimination half-life of 1–3 h
depending on the species (37). GRMS-55 demonstrated a
linear pharmacokinetics and a moderate bioavailability fol-
lowing IP dosing. It was quite quickly eliminated from rat
plasma with elimination half-life values of 22 min in male
and 21 min in female rats. However, a 2-compartment mod-
el was more relevant to describe pharmacokinetics of
GRMS-55 in female rats, while a 1-compartment model
was more suitable in the case of male rodents. The limita-
tion of this study is that the effects of the rat strain and sex
on pharmacokinetics of the investigated compounds were
not evaluated, because different rat sexes of each strain
(Wistar and Lewis) were used in the experiments.
Therefore, it was not possible to assess the impact of these
factors on the values of pharmacokinetic parameters of the
tested compounds. Moreover, a more in-depth investigation
of GRMS-55 pharmacokinetics is required to accurately de-
termine the structural pharmacokinetic model for this com-
pound. The results of the present study indicate that the
pharmacokinetic model for GRMS-55 is highly dependent
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on the experimental data available as the concentration-time
data were captured by different models (1- vs 2-compart-
ment) depending on the groups of rats studied or the applied
route of administration.
LPS-induced endotoxemia is a model of sepsis used to
evaluate anti-inflammatory agents, as LPS is a crucial trigger
of inflammation in bacterial infection and sepsis. However,
this test may be also used to evaluate the TNF-α reducing
potential of investigated compounds. PDE inhibitors have
been previously tested as anti-inflammatory agents in LPS-
induced sepsis in rodents. Cilostazol, a PDE3 selective inhib-
itor, has been shown to improve the survival of mice in a
model of LPS-induced septic shock. TNF-α, IL-1β, and IL-6
levels were significantly decreased in animals pre-treated with
this compound at a dose range of 1–5 mg kg−1. Moreover,
rolipram and other PDE4 inhibitor, CP-77059 reduced se-
rum TNF-α levels and mortality in the LPS-induced septic
shock model. PK/PD modeling is rather rarely used in assess-
ing the potency of anti-inflammatory drugs in endotoxemia
models, although, there have already been some attempts to
use it to evaluate the potency of some compounds, including
(±)-LSF and PTX (19), to assess the nature and the potency of
interactions between drugs (38), but also to elucidate the
mechanism of anti-inflammatory activity (39). In amicemodel
of endotoxemia, R-(−)-LSF as well as PTX have demonstrat-
ed strong anti-inflammatory properties. IC50 value for the in-
hibition of TNF-α release estimated for R-(−)-LSF was 1.61
and 0.47 mg L−1 for PTX (19). In turn, in the experiment in
rats using cAMP as a marker of pharmacological response,
the IC50 value for the the inhibition of cAMP degradation
was 3.43 for (±)-LSF and 4.48 mg L−1 for PTX. In the latter
study, an additive interaction between themwas assumed, and
a modified indirect response model was utilized to assess the
potency of these compounds. In the present study, similarly to
the earlier experiments in mice, we used TNF-α plasma levels
as a marker of pharmacological response. (±)-LSF demon-
strated the IC50 value for the inhibition of TNF-α release
equal to 5.8, while for PTX it was 14.0 mg L−1, so (±)-LSF
was ~2.4 times stronger than PTX. GRMS-55 in this test
exhibited quite strong inhibitory properties expressed as IC50
equal to ~1.1 mg L−1, while rolipram was the most potent
inhibitor of TNF-α release demonstrating almost 3 times
higher activity than GRMS-55 and approx. 16 and 39 times
higher potency than those of (±)-LSF and PTX, respectively.
The results of this experiment indicate that the inhibition of
TNF-α release is associated with PDE4B inhibitory activity of
each compound, while PDE4D inhibition is not necessary to
obtain the therapeutic effect. The simultaneous inhibition of
other PDE subtypes, such as PDE7A, PDE3A, or PDE1B
may possibly augment the therapeutic effect in LPS-induced
endotoxemia, as GRMS-55, which demonstrates strong
PDE1B and PDE7A and moderate PDE3A inhibitory prop-
erties, was ~5.5 more potent than (±)-LSF in inhibiting
TNF-α release, while it is only ~2 times more potent as a
PDE4B inhibitor.
The PK/PD model developed in this study to describe
TNF-α changes following LPS administration to rats is a mod-
ified indirect response model (19) with implemented transit
compartments reflecting the signal transduction process that
takes place from the moment of LPS administration to an
increase in levels of TNF-α in the rat blood. Individual transit
compartments correspond to subsequent stages leading to
TNF-α release, such as binding of LPS to TLR4 receptor,
subsequent signal transmission, TNF-α gene transcription,
TNF-α protein formation and its release from immune cells
into the blood. The τ parameter value is related to the dura-
tion of these stages. Whereas the kin value is the time limited
zero-order rate constant of production of a precursor occur-
ring on the signaling pathway leading to TNF-α release. The
assumption of this model is that the tested compounds act by
inhibiting the inflammatory mediator called the precursor.
This is in agreement with the mechanism of action of
PDE4B inhibitors, as these compounds inhibit the synthesis
of TNF-α mRNA that may be considered a precursor of
TNF-α. Thus, this model closely resembles the mechanism
of development of LPS-induced endotoxemia and the mech-
anism of action of the tested compounds. Furthermore, the
number of estimated parameters in the model developed in
this study is reduced. By using a signal transduction, it was
possible to eliminate one lag time parameter that was used
in the previous studies (19), which was rather an artificial
parameter describing the delay in the observed effect of the
test compounds in relation to they appearance in blood.
RA is a chronic and debilitating autoimmune disorder lead-
ing to disability and a significant deterioration of the quality of
life. CIA in rat is the most recognized and clinically relevant
animal model of RA, characterized by the destruction of bones
and cartilage, the presence of autoantibodies, and an involve-
ment of TNF-α as the main mediator leading to the develop-
ment of this disease. Some PDE inhibitors have been already
tested in CIA. Selective PDE4 inhibitors, such as rolipram and
apremilast have been demonstrated to alleviate the disease de-
velopment and progression. Rolipram exhibited a preventive
role in the development of CIA by decreasing a clinical score
and reduced TNF-α and IFN-γmRNA synthesis in cells isolat-
ed from draining lymph nodes of rats with CIA (40). A dual
PDE4/7 inhibitor – YM-393059 ameliorated the clinical signs
of the CIA in mice by suppressing TNF-α and IL-1β produc-
tion and suppressing humoral immune response. Interestingly,
this compound exhibited a reduced emetogenic potential com-
pared to that of a selective PDE4 inhibitor (41). The results of
the present study confirm the therapeutic potential of selective
PDE4 inhibitors, as the most potent PDE4 inhibitor among the
investigated compounds – rolipram exhibited the strongest
therapeutic potential in CIA. The PK/PD analysis performed
in this study allowed for the quantitative evaluation of the
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potency and comparison of each investigated compound by
correlating the collected concentration-effect data. The IC50
values for an inhibition of the production component (kin(t)),
which represents the disease progression, were estimated for
the three investigated compounds, namely rolipram, GRMS-
55, and (±)-LSF. GRMS-55 was ~26 times less potent than the
selective PDE4 inhibitor – rolipram, but ~4 times stronger in
inhibiting the disease progression than (±)-LSF. These results
imply that probably PDE4B inhibition is mainly responsible for
the antiarthritic potential of the investigated compounds, but
PDE7A inhibitionmay also play a role in the treatment process,
as GRMS-55 was ~4 times stronger than (±)-LSF, which was
only ~2 times weaker as a PDE4B inhibitor in vitro than
GRMS-55. Nevertheless, further studies using selective PDE7
inhibitor in CIA model are necessary to elucidate the possible
role of selective PDE7 inhibition in the treatment of immune-
mediated arthritis. With no doubt, it has been demonstrated
that an inhibition of PDE4D is not necessary to achieve a ther-
apeutic effect in this disease model. In general, it can be con-
cluded that the lower is the value of IC50 for a particular com-
pound with respect to PDE4B, the higher is the potency of this
compound in reducing progression of CIA. GRMS-55 and (±)-
LSF, which have higher IC50 values against hrPDE4B, demon-
strated a weaker antiarthritic potential than rolipram in this
study. However, it should be kept in mind that they may be
used at higher doses due to their favorable safety profiles, which
may make up for the lower potency.
In this study, we modified the PK/PD/DIS progression
model developed earlier by Earp et al. (18). A relative size of
each rat paw was normalized to the size of the same paw at the
day of the first immunization. Thus, paw size at day 0 was fixed
to 1, and initial conditions for each transit compartment were
fixed to 1 as well. The natural paw growth rate was calculated
based on the study performed in healthy female Lewis rats (21)
and fixed. Imax values were fixed to 1. The transit compartments
were implemented to illustrate the delay in the onset of paw
swelling from the time of immunization and to illustrate the
delay of the effect occurrence following the administration of
the drug. The use of transduction compartments was beneficial,
as it made the model more relevant to the mechanism of the
CIA development. Following collagen type II administration,
the binding between the peptide and the MHC molecules
occurs, the specific antibodies are produced, T and B cells are
recruited, and the production of cytokines, such as TNF-α,
which is also divided into several stages (transcription and trans-
lation) occurs. Therefore, undoubtedly, the pathogenesis of
CIA is a multistep process initiated by the administration of
collagen emulsion, the final effect of which is the appearance
of visible symptoms of the disease, such as swelling and redness
of joints. Moreover, the PDE inhibitors, which exert the thera-
peutic effect, probably do not act directly on the production of
swelling of the paw, as it was assumed in the previously devel-
oped PK/PD/DIS models for other compounds, but they may
interact with various factors preceding the onset of swelling,
such as an increased gene expression of pro-inflammatory cyto-
kines or proliferation of lymphocytes. Thus, the model devel-
oped in this study seems to more closely resemble both the
pathogenesis of the disease and the mechanism of action of
the investigated compounds. Nevertheless, previously devel-
oped models might have been more relevant in studying other
types of drugs, such as biologics, which exert their activity at
other stages of the disease development and may interact with
other targets. Different variants of input components have been
presented in the literature in PK/PD/DIS progression models
to describe a sharp increase of edema after arthritis onset and a
natural remission of the disease in rat CIA. Among others, a
production rate was used by Earp et al. (18), as a function of time
starting at the disease onset and being dependent upon the
degree of swelling. A combination of transduction and indirect
response models has been also previously utilized to this end
(42). In that study, 19 transduction compartments were
employed to describe the time delay to sharp increase of paw
size and 5 more to account for the time delay of natural remis-
sion after disease onset. Moreover, a nonlinear negative feed-
back mechanism was utilized to capture the natural remission.
Unfortunately, all previously developed and tested in this study
models resulted in considerable imprecision of estimated
parameters. Therefore, in the model developed in this study,
similarly as in the previous work of Lon et al. (43), we have
employed the empirical input, where the kdeg is the first-order
rate constant that represents a decline in the zero-order rate
kin(t) and accounts for the natural remission of arthritis after
disease onset. In addition, we utilized transduction compart-
ments accounting for delay between the disease onset and swell-
ing of paws. This way of the defining the production compo-
nent allowed for a satisfactory fit of the model to the experi-
mental data and an effective comparison of the activity of the
tested compounds.
The results of histological examination of paw cross-
sections from rats with CIA are in line with the results of
earlier experiments in rodents with CIA, where symptoms
such as subchondral bone destruction, cartilage disruption,
or synovitis were observed. These manifestations were allevi-
ated by the administration of other, than used in this study,
PDE4 inhibitors, such as apremilast (44). The statistical anal-
ysis of histological scores confirmed that rolipram exhibited
the strongest activity in ameliorating the abovementioned
symptoms of CIA, while GRMS-55 as well as (±)-LSF
exhibited weaker but also significant antiarthritic properties.
CONCLUSION
In conclusion, the investigated PDE inhibitors, namely
GRMS-55 and (±)-LSF exhibit favorable PDE inhibitory pro-
files, which are a good prognosis for their therapeutic
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effectiveness and safety of use. GRMS-55 is a strong
hrPDE7A and hrPDE1B inhibitor with moderate hrPDE4B
and hrPDE3A inhibitory properties. On the other hand, (±)-
LSF is a moderate hrPDE3A and hrPDE4B inhibitor. Both
compounds do not demonstrate activity against hrPDE4D, an
inhibition of which is considered to be responsible for adverse
effects, such as nausea and emesis. It has been demonstrated
that PDE4D inhibitory activity is not essential to obtain ther-
apeutic effect in all tested animal models of immune-related
diseases. In contrast, the potency of PDE4B inhibition appears
to be related to anti-inflammatory properties of the investigat-
ed compounds. GRMS-55 ameliorated ConA-induced hepa-
titis in mice by inhibiting NF-α secretion and reducing the
activity of transaminases. On the other hand, (±)-LSF de-
creased TNF-α levels but failed to reduce the activity of trans-
aminases. This failure might have arisen from STAT4 inhib-
itory properties of (±)-LSF. Both compounds exhibit a mod-
erate activity in LPS-induced endotoxemia model and CIA,
compared to that of a potent pan-PDE4 inhibitor – rolipram,
which most strongly inhibited CIA progression and TNF-α
plasma levels in LPS-induced endotoxemia. Furthermore, all
compounds tested alleviated histological symptoms of arthri-
tis, however, rolipram demonstrated the strongest potency in
reducing subchondral osteoarthritis, while (±)-LSF failed to
significantly diminish this manifestation. The inhibition of
PDE7A seems to display an additional anti-inflammatory ef-
fect, as a strong inhibitor of PDE7A –GRMS-55 demonstrat-
ed ~5.5 and ~4.0 times lower IC50 values in LPS-induced
endotoxemia and CIA, respectively, than (±)-LSF, which is
only a ~2.0 times weaker PDE4B inhibitor than GRMS-55.
The developed in this study PK/PD and PK/PD/DIS pro-
gressionmodels may be used to design future pre-clinical stud-
ies and to assess the potency of new compounds for the treat-
ment of RA and other inflammatory disorders. GRMS-55
and (±)-LSF seem to be promising candidates for further
pre-clinical and clinical studies of immune-related diseases.
ACKNOWLEDGMENTS AND DISCLOSURES
This study was supported by the National Science Centre,
Poland, grant No. 2018/29/N/NZ7/00432 and the statutory
activity of Jagiellonian University Medical College (N42/DBS/
000073). All the experimental procedures involving animals were
performed in accordance with the European Communities
Council Directive of 22 September 2010 (2010/63/EU) on the
protection of animals used for scientific purposes.
Open Access This article is licensed under a Creative
Commons Attribution 4.0 International License, which per-
mits use, sharing, adaptation, distribution and reproduction in
any medium or format, as long as you give appropriate credit
to the original author(s) and the source, provide a link to the
Creative Commons licence, and indicate if changes were
made. The images or other third party material in this article
are included in the article's Creative Commons licence, unless
indicated otherwise in a credit line to the material. If material
is not included in the article's Creative Commons licence and
your intended use is not permitted by statutory regulation or
exceeds the permitted use, you will need to obtain permission
directly from the copyright holder. To view a copy of this
licence, visit http://creativecommons.org/licenses/by/4.0/.
REFERENCES
1. Manning CD, Burman M, Christensen SB, Cieslinski LB, Essayan
DM, Grous M, Torphy TJ, Barnette MS. Suppression of human
inflammatory cell function by subtype-selective PDE4 inhibitors
correlates with inhibition of PDE4A and PDE4B. Br J
Pharmacol. 1999;128:1393–8.
2. Jankowska A, Świerczek A, Chłoń-Rzepa G, Pawłowski M, Wyska
E. PDE7-selective and dual inhibitors: advances in chemical and
biological research. Curr Med Chem. 2017;24:673–700.
3. Fisher D, Smith J, Pillar J, St Denis S, Cheng J. Isolation and
characterization of PDE8A, a novel human cAMP-specific phos-
phodiesterase. Biochem Biophys Res Commun. 1998;246:570–7.
4. Barnes H, Brown Z, Burns A, Williams T. Phosphodiesterase 5
inhibitors for pulmonary hypertension. Cochrane Database Syst
Rev. 2019;1:CD012621.
5. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily:
a new target for the development of specific therapeutic agents.
Pharmacol Ther. 2006;109:366–98.
6. Prickaerts J, Heckman PRA, Blokland A. Investigational phosphodies-
terase inhibitors in phase I and phase II clinical trials for Alzheimer’s
disease. Expert Opin Investig Drugs. 2017;26:1033–48.
7. Gomez L, Breitenbucher JG. PDE2 inhibition: potential for the
treatment of cognitive disorders. Bioorg Med Chem Lett.
2013;23:6522–7.
8. Jankowska A, Świerczek A,Wyska E, Gawalska A, Bucki A, Pawłowski
M, Chłoń-Rzepa G. Advances in discovery of PDE10A inhibitors for
CNS-related disorders. Part 1: overview of the chemical and biological
research. Curr Drug Targets. 2018;19:122–43.
9. Świerczek A,Wyska E, Baś S,WoyciechowskaM,Mlynarski J. PK/
PD studies on non-selective PDE inhibitors in rats using cAMP as a
marker of pharmacological response. Naunyn Schmiedeberg's
Arch Pharmacol. 2017;390:1047–59.
10. Raker VK, Becker C, Steinbrink K, Bodor J, Baier G, Katharina
Raker V, Becker C, Steinbrink K. The cAMP pathway as thera-
peutic target in autoimmune and inflammatory diseases. Front
Immunol. 2016;7:123.
11. Cassim S, Bilodeau M, Vincent C, Lapierre P. Novel immuno-
therapies for autoimmune hepatitis. Front Pediatr. 2017;5:8.
12. YamanakaH.TNF as a target of inflammation in rheumatoid arthritis.
Endocr Metab Immune Disord Drug Targets. 2015;15:129–34.
13. Lv S, HanM, Yi R, Kwon S, Dai C,Wang R. Anti-TNF-α therapy
for patients with sepsis: a systematic meta-analysis. Int J Clin Pract.
2014;68:520–8.
14. Jin S-LC, Lan L, Zoudilova M, Conti M. Specific role of phospho-
diesterase 4B in lipopolysaccharide-induced signaling in mouse
macrophages. J Immunol. 2005;175:1523–31.
15. Robichaud A, Stamatiou PB, Jin S-LC, Lachance N, MacDonald
D, Laliberté F, Liu S, Huang Z, Conti M, Chan C-C. Deletion of
phosphodiesterase 4D in mice shortens α2-adrenoceptor-mediated
19 Page 20 of 21 Pharm Res (2020) 37: 19
anesthesia, a behavioral correlate of emesis. J Clin Invest. 2002;110:
1045–52.
16. Chłoń-Rzepa G, Jankowska A, Ślusarczyk M, Świerczek A,
Pociecha K, Wyska E, Bucki A, Gawalska A, Kołaczkowski M,
Pawłowski M. Novel butanehydrazide derivatives of purine-2,6-
dione as dual PDE4/7 inhibitors with potential anti-inflammatory
activity: design, synthesis and biological evaluation. Eur J Med
Chem. 2018;146:381–94.
17. Bright JJ, Du C, Coon M, Sriram S, Klaus SJ. Prevention of exper-
imental allergic encephalomyelitis via inhibition of IL-12 signaling
and IL-12-mediated Th1 differentiation: an effect of the novel anti-
inflammatory drug lisofylline. J Immunol. 1998;161:7015–22.
18. Earp JC, Dubois DC, Almon RR, JuskoWJ. Quantitative dynamic
models of arthritis progression in the rat. PharmRes. 2009;26:196–
203.
19. Wyska E. Pharmacokinetic-pharmacodynamic modeling of meth-
ylxanthine derivatives in mice challenged with high-dose lipopoly-
saccharide. Pharmacology. 2010;85:264–71.
20. Świerczek A,Wyska E, Pociecha K, Baś S,Mlynarski J. Influence of
inflammatory disorders on pharmacokinetics of lisofylline in rats:
implications for studies in humans. Xenobiotica. 2019;49:1209–20.
21. Liu D, Lon HK, Dubois DC, Almon RR, Jusko WJ, Edu W.
Population pharmacokinetic-pharmacodynamic-disease progres-
sion model for effects of anakinra in Lewis rats with collagen-
induced arthritis. J Pharmacokinet Pharmacodyn. 2011;38:769–
86.
22. Earp JC, Dubois DC, Molano DS, Pyszczynski NA, Keller CE,
Almon RR, JuskoWJ. Modeling corticosteroid effects in a rat mod-
el of rheumatoid arthritis I: mechanistic disease progression model
for the time course of collagen-induced arthritis in Lewis rats. J
Pharmacol Exp Ther. 2008;326:532–45.
23. Kwon B-J, Lee S-H, KimD-B, Park H-J, Jang S-W, Ihm S-H, Kim
H-Y, Seung K-B. A randomized comparison study assessing the
impact of cilostazol on the heart rate and arrhythmias by 24-hour
ambulatory holter electrocardiographic monitoring after drug-
eluting stent implantation for coronary artery disease. J
Atheroscler Thromb. 2015;22:152–64.
24. Yu J, Wolda SL, Frazier AL, Florio VA, Martins TJ, Snyder PB,
Harris EA, McCaw KN, Farrell CA, Steiner B, Bentley JK, Beavo
JA, Ferguson K, Gelinas R. Identification and characterisation of a
human calmodulin-stimulated phosphodiesterase PDE1B1. Cell
Signal. 1997;9:519–29.
25. Michie AM, Lobban M, Müller T, Harnett MM, Houslay MD.
Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodies-
terase activity following ligation of the T cell antigen receptor on
thymocytes: analysis using the selective inhibitors erythro-9-(2-hy-
droxy-3-nonyl)-adenine (EHNA) and rolipram. Cell Signal. 1996;8:
97–110.
26. Cheung PP, Yu L, Zhang H, Colman RW. Partial characterization
of the active site human platelet cAMP phosphodiesterase, PDE3A,
by site-directedmutagenesis. Arch Biochem Biophys. 1998;360:99–
104.
27. Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS,
Nicholson AG, Barnes PJ, Barnette MS, Giembycz MA.
Discovery of BRL 50481 [3-(N, N-dimethylsulfonamido)-4-meth-
yl-nitrobenzene], a selective inhibitor of phosphodiesterase 7:
in vitro studies in human monocytes. Mol Pharmacol. 2004;66:
1679–89.
28. Turko IV, Francis SH, Corbin JD. Potential roles of conserved
amino acids in the catalytic domain of the cGMP-binding cGMP-
specific phosphodiesterase (PDE5). J Biol Chem. 1998;273:6460–6.
29. Su GL, Goyert SM, Fan M-H, Aminlari A, Gong KQ, Klein RD,
Myc A, Alarcon WH, Steinstraesser L, Remick DG, Wang SC.
Activation of human andmouseKupffer cells by lipopolysaccharide
is mediated by CD14. Am J Physiol Liver Physiol. 2002;283:G640–
5.
30. Tavares JL, Wangoo A, Dilworth P, Marshall B, Kotecha S, Shaw
RJ. Thalidomide reduces tumour necrosis factor-alpha production
by human alveolar macrophages. Respir Med. 1997;91:31–9.
31. Cho JY, Park JS, Baik KU, Lee JG, Kim HP, Yoo ES, Park MH.
Differential effect of phosphodiesterase IV inhibitor RP73401 on
various inflammatory and immune responses relevant to rheuma-
toid arthritis. Pharmacol Res. 2004;49:423–31.
32. Wang HX, Liu M,Weng SY, Li JJ, Xie C, He HL, GuanW, Yuan
YS, Gao J. Immune mechanisms of Concanavalin a model of au-
toimmune hepatitis. World J Gastroenterol. 2012;18:119–25.
33. Gantner F, Kusters S, Wendel A, Hatzelmann A, Schudt C, Tiegs
G. Protection from T cell-mediated murine liver failure by phos-
phodiesterase inhibitors. J Pharmacol Exp Ther. 1997;280:53–60.
34. Goto M, Tanaka Y, Murakawa M, Kadoshima-Yamaoka K, Inoue
H, Murafuji H, Nagahira A, Kanki S, Hayashi Y, Nagahira K,
Ogata A, Miura K, Nakatsuka T, Chamoto K, Fukuda Y,
Nishimura T. Inhibition of phosphodiesterase 7A ameliorates
Concanavalin a-induced hepatitis in mice. Int Immunopharmacol.
2009;9:1347–51.
35. Yang Z, Chen M, Fialkow LB, Ellett JD, Wu R, Nadler JL.
Inhibition of STAT4 activation by lisofylline is associated with the
protection of autoimmune diabetes. Ann NYAcad Sci. 2003;1005:
409–11.
36. Wang Y, Feng D,Wang H, XuM-J, Park O, Li Y, Gao B. STAT4
knockout mice are more susceptible to concanavalin A-induced T-
cell hepatitis. Am J Pathol. 2014;184:1785–94.
37. Krause W, Kühne G. Pharmacokinetics of rolipram in the rhesus
and cynomolgus monkeys, the rat and the rabbit. Studies on species
differences. Xenobiotica. 1988;18:561–71.
38. Chakraborty A, Yeung S, Pyszczynski NA, Jusko WJ.
Pharmacodynamic interactions between recombinant mouse
interleukin-10 and prednisolone using a mouse endotoxemia mod-
el. J Pharm Sci. 2005;94:590–603.
39. Gozzi P, Påhlman I, Palmér L, Grönberg A, Persson S.
Pharmacokinetic-pharmacodynamic modeling of the immunomo-
dulating agent susalimod and experimentally induced tumor ne-
crosis factor-alpha levels in the mouse. J Pharmacol Exp Ther.
1999;291:199–203.
40. Nyman U, Ussener A, Larsson E, Lorentzen J, Klareskog L.
Amelioration of collagen II-induced arthritis in rats by the type
IV phosphodiesterase inhibitor Rolipram. Clin Exp Immunol.
1997;108:415–9.
41. Yamamoto S, Sugahara S, Ikeda K, Shimizu Y. Amelioration of
collagen-induced arthritis in mice by a novel phosphodiesterase 7
and 4 dual inhibitor, YM-393059. Eur J Pharmacol. 2007;559:
219–26.
42. Liu DY, Lon HK, Wang YL, Dubois DC, Almon RR, Jusko WJ.
Pharmacokinetics, pharmacodynamics and toxicities of methotrex-
ate in healthy and collagen-induced arthritic rats. Biopharm Drug
Dispos. 2013;34:203–14.
43. Lon HK, Liu D, Zhang Q, Dubois DC, Almon RR, Jusko WJ.
Pharmacokinetic-pharmacodynamic disease progression model
for effect of etanercept in Lewis rats with collagen-induced arthritis.
Pharm Res. 2011;28:1622–30.
44. McCann FE, Palfreeman AC, AndrewsM, PerocheauDP, Inglis JJ,
Schafer P, FeldmannM,Williams RO, Brennan FM. Apremilast, a
novel PDE4 inhibitor, inhibits spontaneous production of tumour
necrosis factor-alpha from human rheumatoid synovial cells and
ameliorates experimental arthritis. Arthritis Res Ther. 2010;12:
107.
Publisher’s Note Springer Nature remains neutral with regard
to jurisdictional claims in published maps and institutional
affiliations.
Pharm Res (2020) 37: 19 Page 21 of 21 19
